Karyopharm Therapeutics Inc.

Epix Delaware, Inc.

Biogen Ma Inc.

Microdose Therapeutx, Inc.

Epix Pharmaceuticals, Inc.

Other

Nanotherapeutics, Inc.

Cytopathfinder, Inc.

Galenea Corp.

Sharon Shacham

Dilara McCauley

Sharon Shechter

Vincent Premaratna Sandanayaka

Erkan Baloglu

Yael Marantz

Oren Becker

William Senapedis

Silvia Noiman

Dale S Dhanoa

Ori Kalid

Yosef Landesman

Gali Golan

Dongli Chen

Mercedes Lobera

Boaz Inbal

Pradyumna Mohanty

Srinivasa Rao Cheruku

Shay Bar-Haim

Alexander Heifetz

Anurag Sharadendu

Ashis K Saha

Pini Orbach

Laurence Wu

Merav Fichman

Zhaoda Zhang

Trinayan Kashyap

Jian Lin

Xiang Y Yu

Rosa Melendez

Michael Kauffman

Efrat Ben-Zeev

A Sekar Reddy

Vincent Jacques

Hanoch Senderowitz

Raphael Nudelman

Nili Schutz

Robert Christian Penland

Michael Xie

Kimberley Gannon

Shomir Ghosh

Victor J Cee

Brian Alan Lanman

Jennifer Elizabeth Golden

Roland W Burli

Venkitasamy Kesavan

Susana C Neira

Steffi Koerner

Laurence I Wu

Tami Rashal

Jean-Richard Saint-Martin

Dilârâ McCauley

Rosa E Melendez

Roland Burli

Vincent P Sandanayaka

Robert C Penland

Susana Neira

Dilara Mccauley

Dilara Mccaulay

Vincent P Sandanyaka

The invention generally relates to substituted benzofuranyl and substituted benzoxazolyl compounds, and more particularly to a compound represented by Structural Formula A: or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of Structural Formula A, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment of cancer (e.g., mantle cell lymphoma), and other diseases and disorders.

Substituted benzofuranyl and benzoxazolyl compounds and uses thereof

The invention generally relates to nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by structural formula I.

Hydrazide containing nuclear transport modulators and uses thereof

The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds of formula I or their pharmaceutically acceptable salts, and methods of using said compounds, salts and compositions in the treatment of various disorders associated with CRM1 activity.

Nuclear transport modulators and uses thereof

The invention generally relates to nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by structural formula I: or a pharmaceutically acceptable salt thereof, wherein the values and alternative values for the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.

Compounds of formula I: and pharmaceutically acceptable salts, solvates, or hydrates thereof, pharmaceutical compositions comprising the compounds of formula I, and methods of making and using the compounds, salts, solvates, or hydrates and the compositions in the treatment of various disorders associated with CRM1 activity.

Compounds of formula I: and pharmaceutically acceptable salts, solvates, or hydrates thereof, pharmaceutical compositions comprising the compounds of formula I, and methods of using the compounds, salts, solvates, or hydrates and the compositions in the treatment of various disorders associated with CRM1 activity.

Compounds of formula I: and pharmaceutically acceptable salts, hydrates, or solvates thereof, pharmaceutical compositions comprising the compounds of formula I, and methods of using such compounds and compositions to treat various disorders associated with CRM1 activity.

The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds of formula I, and methods of using the compounds, salts and compositions in the treatment of various disorders associated with CRM1 activity.

The invention generally relates to substituted benzofuranyl compounds and, more particularly, to a compound represented by Structural Formula 1a: (I) or a pharmaceutically acceptable salt thereof. The invention also includes the synthesis and use of the compound of Structural Formula 1a, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment of diseases or disorder selected from cancer (e.g., lymphoma, such as mantle cell lymphoma), a neurodegenerative disease, an inflammatory diseases or an immune system disease (e.g., a T-Cell mediated autoimmune disease) in a subject in need thereof. The method comprises administering to a subject in need thereof a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof, or a composition comprising a compound of the invention, or a pharmaceutically acceptable salt thereof. 

(S,E)-3-(6-aminopyridin-3-yl)-N-((5-(4-(3-fluoro-3-methylpyrrolidine-1-carbonyl)phenyl-7-(4-fluorophenyl)benzofuran-2-yl)methyl)acrylamide for the treatment of cancer

Growing community of inventors

Newton, MA, United States of America

Sharon Shacham